ScinoPharm Taiwan (Stock Code: 1789) held an investor conference today to report on its 2024 operational performance and business developments. The company achieved a consolidated annual revenue of NT$3.406 billion, marking a moderate 7% growth. Net profit after tax reached NT$339 million, reflecting an 18% year-over-year increase, with earnings per share (EPS) rising to NT$0.43.

ScinoPharm Taiwan (SPT) (stock code 1789) has not only solidified its position in the US and EU pharmaceutical markets, but is continuing to extend its reach into promising emerging markets, demonstrating its commitment to expand its global footprint.

ScinoPharm Taiwan (stock code 1789) reported consolidated revenue of NT$1.646 billion for the first half of 2024, with a post-tax net profit of NT$215 million, representing a 117% increase compared to the same period last year.

ScinoPharm Taiwan (stock code 1789) announced today that its consolidated revenue for the first quarter reached NT$883 million, representing an increase of 36.21% compared to the same period last year. The sales momentum remained robust in the first quarter of 2024, resulting in increased shipments. And The first quarter consolidated net profit reached NT$140 million, marking a remarkable growth of 233% compared to the same period last year.